Medical Condition News

RSS

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer.

12 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

Genetic variations do not improve ability to predict risk of AD: Study

Although genome-wide analysis identified two genetic variations associated with Alzheimer disease, these variations did not improve the ability to predict the risk of AD, according to a study in the May 12 issue of JAMA.

12 May 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs).

12 May 2010

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Vical Incorporated announced the publication in the June issue of Melanoma Research of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy reviewed results from the Phase 2 trial and previous clinical studies of Allovectin-7®.

12 May 2010

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.

12 May 2010

Academic scientist receives $125,000 from ADDF/LBDA program to study LBD

The Alzheimer's Drug Discovery Foundation and the Lewy Body Dementia Association announced today the recipient of their first partnership research award through the Lewy Body Dementia Biomarker Research Program.

12 May 2010

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

“We have very good experience with Aldara in Europe and we look forward to provide AK patients with a new product with improved tolerability that builds on the efficacy of imiquimod”

12 May 2010

Caffeine helps shift workers make fewer errors: Cochrane researchers

Caffeine can help those working shifts or nights to make fewer errors, according to a new study by Cochrane researchers. The findings have implications for health workers and for any industry relying on shift or night work, such as transportation.

12 May 2010

Gap between Hispanic and white asthma sufferers widen in the use daily medications

The gap between the proportion of black and white Americans with asthma who took an inhaled or oral medicine daily to prevent attacks grew wider between 2003 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

12 May 2010

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

A study to be published in the latest issue of The Cochrane Library and led by researchers at the University of Edinburgh and supported by colleagues at the Peninsula Dental School, the University of Ottawa and UCL Eastman Dental Institute, suggests that the treatment of serious gum (periodontal) disease in diabetics with Type 2 diabetes may lower their blood sugar levels.

12 May 2010

Researchers discover molecular mechanism behind smoking cessation effect

The tobacco addiction epidemic is a major public health problem worldwide. Professor Zhao Baolu and his group from the State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences set out to tackle this problem. After 20 years of innovative research, they have developed a novel tea filter to treat cigarette addiction and have discovered the molecular mechanism behind the smoking cessation effect.

12 May 2010

New computer-based tool developed to benefit cancer patients

Cancer patients and doctors are finally getting on the same page about cancer survivorship, thanks to a free new tool that can benefit anyone who has been diagnosed with cancer.

12 May 2010

Regular exercise plays important role in improving wellbeing of patients with schizophrenia: Review

Regular exercise can play an important a role in improving the physical and mental wellbeing of individuals with schizophrenia, according to a review published in The Cochrane Library.

12 May 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma.

12 May 2010

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

The ZKB TECHNOPARK® Pioneer Award, which has been sponsored by the Zürcher Kantonalbank since 2000, was presented for the 20th time at TECHNOPARK® Zurich. The award is given for technological innovations which - thanks to pioneering entrepreneurial achievements - are about to be launched on the market. This year's award winner is Neurimmune Therapeutics AG, represented by Dr. Jan Grimm, Professor Christoph Hock, Professor Roger Nitsch and Dr. Michael Salzmann.

12 May 2010

Japanese MHLW approves St. Jude Medical's AnalyST ICD with ST Monitoring device

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) of its AnalyST™ implantable cardioverter defibrillator (ICD) with ST Monitoring, a revolutionary device that not only provides life-saving therapy for dangerously fast heart rhythms, but also continuously monitors electrical changes (called ST segments) to help physicians monitor for cardiac problems.

12 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

St. Jude Medical launches Promote Quadra CRT-D in Europe

St. Jude Medical, Inc., a global medical device company, today announced the European launch of its Promote Quadra™ cardiac resynchronization therapy defibrillator (CRT-D). The Promote Quadra CRT-D is the industry's first quadripolar pacing system, which offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

12 May 2010

CHD mortality rate in Ontario decreased by 35%: Study

From 1994 to 2005 in Ontario, Canada, there was a 35 percent decrease in the rate of deaths from coronary heart disease, with about half of this reduction associated with improvements in traditional CHD risk factors such as total cholesterol levels and systolic blood pressure, according to a study in the May 12 issue of JAMA.

12 May 2010

Medical Condition News

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Genetic variations do not improve ability to predict risk of AD: Study

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Academic scientist receives $125,000 from ADDF/LBDA program to study LBD

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Caffeine helps shift workers make fewer errors: Cochrane researchers

Gap between Hispanic and white asthma sufferers widen in the use daily medications

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

Researchers discover molecular mechanism behind smoking cessation effect

New computer-based tool developed to benefit cancer patients

Regular exercise plays important role in improving wellbeing of patients with schizophrenia: Review

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

Japanese MHLW approves St. Jude Medical's AnalyST ICD with ST Monitoring device

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

St. Jude Medical launches Promote Quadra CRT-D in Europe

CHD mortality rate in Ontario decreased by 35%: Study

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News